Regeneus Limited
(ASX:RGS) posted gains yesterday as it slimmed its first half loss by 10 per cent to $5.7 million thanks to boosted revenues.
The regenerative medicine company saw its revenue grow 46 per cent in the six months to the end of December with licence fees and human health revenue showing strong gains.
The company successfully raised $6.17 million in capital in the period and received $3.73 million from the R&D tax incentive.
Looking forward the company says its focussed on progressing its veterinary products while also furthering trials for its human product Progenza.
